CN110114083A - 一种预防和治疗脂肪肝的方法 - Google Patents
一种预防和治疗脂肪肝的方法 Download PDFInfo
- Publication number
- CN110114083A CN110114083A CN201780078127.7A CN201780078127A CN110114083A CN 110114083 A CN110114083 A CN 110114083A CN 201780078127 A CN201780078127 A CN 201780078127A CN 110114083 A CN110114083 A CN 110114083A
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- prevent
- subject
- treat fatty
- plasminogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004930 Fatty Liver Diseases 0.000 title abstract 3
- 206010019708 Hepatic steatosis Diseases 0.000 title abstract 3
- 208000010706 fatty liver disease Diseases 0.000 title abstract 3
- 231100000240 steatosis hepatitis Toxicity 0.000 title abstract 3
- 102000013566 Plasminogen Human genes 0.000 abstract 2
- 108010051456 Plasminogen Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种预防和/或治疗受试者脂肪肝及其相关病症的方法,包括给药受试者有效量的纤溶酶原;另一方面,本发明还涉及用于预防和/或治疗受试者脂肪肝及其相关病症的包含纤溶酶原的药物、药物组合物、制品、试剂盒。
Description
PCT国内申请,说明书已公开。
Claims (35)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2016/110168 | 2016-12-15 | ||
CN2016110168 | 2016-12-15 | ||
CNPCT/CN2016/110172 | 2016-12-15 | ||
CN2016110172 | 2016-12-15 | ||
PCT/CN2017/089047 WO2018107688A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗脂肪肝的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110114083A true CN110114083A (zh) | 2019-08-09 |
Family
ID=62557882
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780078105.0A Pending CN110366425A (zh) | 2016-12-15 | 2017-06-19 | 一种预防动脉粥样硬化及其并发症的方法 |
CN201780078118.8A Pending CN110167583A (zh) | 2016-12-15 | 2017-06-19 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
CN201780078127.7A Pending CN110114083A (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗脂肪肝的方法 |
CN201780078126.2A Pending CN110114082A (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗脂肪代谢紊乱及其相关病症的方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780078105.0A Pending CN110366425A (zh) | 2016-12-15 | 2017-06-19 | 一种预防动脉粥样硬化及其并发症的方法 |
CN201780078118.8A Pending CN110167583A (zh) | 2016-12-15 | 2017-06-19 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780078126.2A Pending CN110114082A (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗脂肪代谢紊乱及其相关病症的方法 |
Country Status (7)
Country | Link |
---|---|
US (4) | US11547746B2 (zh) |
EP (4) | EP3556391A4 (zh) |
JP (4) | JP7160351B2 (zh) |
CN (4) | CN110366425A (zh) |
CA (4) | CA3047167A1 (zh) |
TW (9) | TW201822812A (zh) |
WO (8) | WO2018107690A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017101871A1 (zh) * | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗心血管病的新方法 |
TW201822812A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療肥胖症的方法 |
CN110121357A (zh) | 2016-12-15 | 2019-08-13 | 泰伦基国际有限公司 | 一种治疗糖尿病的新方法 |
US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
JP7194440B2 (ja) | 2016-12-15 | 2022-12-22 | タレンゲン インターナショナル リミテッド | 心臓病変を改善するための方法 |
EP3556380A4 (en) * | 2016-12-15 | 2020-05-13 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN |
WO2018233604A1 (zh) * | 2017-06-19 | 2018-12-27 | 泰伦基国际有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
JP7616698B2 (ja) * | 2020-02-26 | 2025-01-17 | タレンゲン インターナショナル リミテッド | 血圧異常症を予防及び治療する方法並びに薬剤 |
WO2021190563A1 (zh) | 2020-03-24 | 2021-09-30 | 泰伦基国际有限公司 | 一种治疗亨廷顿病的方法和药物 |
CA3182911A1 (en) | 2020-05-11 | 2021-11-18 | Talengen International Limited | Method and drug for treating spinal muscular atrophy |
CN112056563A (zh) * | 2020-09-15 | 2020-12-11 | 王胜林 | 用于修复脂质代谢障碍的营养素组合物及其应用 |
CN113041247A (zh) * | 2021-04-21 | 2021-06-29 | 中山大学孙逸仙纪念医院 | 伊玛替尼在防治新型冠状病毒及并发症药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030054988A1 (en) * | 2000-11-02 | 2003-03-20 | Weidong-Richard Ji | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
CN102482338A (zh) * | 2009-07-10 | 2012-05-30 | 斯路姆基因公司 | 纤溶酶原和纤溶酶的变体 |
CN103384722A (zh) * | 2011-01-05 | 2013-11-06 | 斯路姆基因公司 | 纤溶酶原和纤溶酶变体 |
US20130310305A1 (en) * | 2011-02-10 | 2013-11-21 | Trustees Of Dartmouth College | Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4245051A (en) | 1978-03-30 | 1981-01-13 | Rockefeller University | Human serum plasminogen activator |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
DE3515869A1 (de) | 1985-05-03 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung optisch aktiver azolderivate |
JPS62153224A (ja) | 1985-12-27 | 1987-07-08 | Green Cross Corp:The | プラスミノゲン製剤 |
GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
JP2764264B2 (ja) | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
AT402367B (de) | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
WO1994001128A1 (en) * | 1992-07-01 | 1994-01-20 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
US5520912A (en) | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
DK125693D0 (zh) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
CA2295925A1 (en) | 1997-06-26 | 1999-01-07 | Karolinska Innovations Ab | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
US7317003B2 (en) | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
US6465424B1 (en) * | 1999-02-17 | 2002-10-15 | Bristol-Myers Squibb Company | Anti-angiogenic agent and method for inhibiting angiogenesis |
WO2000049871A1 (en) * | 1999-02-24 | 2000-08-31 | Henry Ford Health System | An anti-angiogenic kringle protein and its mutants |
US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
US20020159992A1 (en) | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
US20070264194A1 (en) * | 2001-08-10 | 2007-11-15 | The Scripps Research Institute | Peptides That Bind To Atherosclerotic Lesions |
US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
CN1408431A (zh) | 2001-09-21 | 2003-04-09 | 北京华兴生生物技术有限公司 | 治疗与新生血管生成相关疾病的基因工程药物 |
US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
EP1472346A2 (de) | 2002-02-06 | 2004-11-03 | N-Zyme BioTec GmbH | Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen |
US20050124036A1 (en) * | 2002-02-06 | 2005-06-09 | Rudy Susilo | Method for producing recombinant proteins in micro-organisms |
US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
AU2003301809A1 (en) | 2002-05-13 | 2004-06-07 | Children's Hospital Los Angeles | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
NZ537006A (en) | 2002-05-17 | 2008-01-31 | Esperion Therapeutics Inc | The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ |
CN101396559A (zh) | 2002-12-06 | 2009-04-01 | 法布罗根股份有限公司 | 糖尿病等的治疗 |
CN1726191A (zh) | 2002-12-10 | 2006-01-25 | 惠氏公司 | 用作纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代的吲哚氧代-乙酰氨基乙酸衍生物 |
CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
EP1666469A4 (en) | 2003-09-11 | 2008-12-03 | Inst Med Molecular Design Inc | INHIBITOR OF PLASMINOGENACTIVATORINHIBITOR-1 |
US20080017694A1 (en) | 2003-09-24 | 2008-01-24 | Alexander Schnell | Braze Alloy And The Use Of Said Braze Alloy |
JP4740531B2 (ja) | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
DE602005022692D1 (de) | 2004-04-22 | 2010-09-16 | Talecris Biotherapeutics Inc | Recombinant modifiziertes plasmin |
US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
WO2006095713A1 (ja) | 2005-03-08 | 2006-09-14 | Institute Of Medicinal Molecular Design. Inc. | プラスミノゲンアクチベータインヒビター-1阻害剤 |
WO2006102395A2 (en) * | 2005-03-22 | 2006-09-28 | Medstar Health Inc | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
EP2000145A4 (en) | 2006-03-24 | 2010-08-25 | Rohto Pharma | AGENT FOR ENHANCING METABOLIC SYNDROME |
DK2056865T3 (en) | 2006-08-28 | 2014-03-24 | Omnio Healer Ab | Hitherto unknown medicinal products for the prevention and treatment of gum disease, improvement of healing of gums in the gums and promotion of dental and oral health |
JP5566105B2 (ja) | 2006-08-28 | 2014-08-06 | オムニオ・ヒーラー・アクチボラゲット | 感染症に対する候補薬 |
CA2666670A1 (en) | 2006-10-20 | 2008-05-02 | Dow Global Technologies Inc. | Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
CN101015686B (zh) | 2007-02-06 | 2010-05-19 | 中国人民解放军军事医学科学院基础医学研究所 | 一种溶栓药物增效剂及其制备方法 |
US20080200387A1 (en) | 2007-02-15 | 2008-08-21 | Hua-Lin Wu | Anti-angiogenic protein, composition and use thereof |
AR067446A1 (es) | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
AT505574B1 (de) * | 2007-08-10 | 2009-09-15 | Affiris Forschungs & Entwicklungs Gmbh | Mimotope zur behandlung von atherosklerose |
US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
EP2201946A4 (en) | 2007-10-23 | 2012-01-25 | Inst Med Molecular Design Inc | HAMMER OF PAI-1 PRODUCTION |
CN101918548B (zh) * | 2007-11-29 | 2013-10-16 | 泰勒克里斯生物治疗学公司 | 重组修饰的纤溶酶 |
KR101712208B1 (ko) | 2008-01-09 | 2017-03-03 | 인트렉손 코포레이션 | Pai―1 작용의 치료학적 억제제 및 이의 사용 방법 |
US20090208448A1 (en) | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
US20100209350A1 (en) * | 2008-12-30 | 2010-08-19 | Andreas Pfuetzner | Biomarkers for Adipose Tissue Activity |
US20120053222A1 (en) | 2009-01-23 | 2012-03-01 | Mark Gorrell | Novel Metabolic Disease Therapy |
CN102378753B (zh) | 2009-03-31 | 2016-03-02 | 肾脏科学股份有限公司 | 纤溶酶原激活物抑制因子-1抑制剂 |
EP2424561A2 (en) | 2009-04-30 | 2012-03-07 | Catherine Blondel | Methods for treating ocular conditions |
EP2464371B1 (en) | 2009-08-12 | 2016-03-16 | Cornell University | Methods for preventing or treating metabolic syndrome |
CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
CN101897925B (zh) * | 2009-12-16 | 2015-04-29 | 成都百康医药工业药理毒理研究院 | 一种治疗代谢综合症的药物组合物 |
EP2566890A4 (en) | 2010-05-03 | 2013-11-20 | Abbvie Inc | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE |
US9044458B2 (en) * | 2010-08-09 | 2015-06-02 | The Johns Hopkins University | Inhibition of tat activating regulatory DNA-binding protein 43 |
CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
CA2829051C (en) | 2011-03-03 | 2020-04-28 | Tersus Pharmaceuticals, LLC | Compositions and methods comprising c16:1n7-palmitoleate |
CN102199587B (zh) * | 2011-03-24 | 2013-06-19 | 广东药学院 | 人纤溶酶原功能性突变体及其制备方法和应用 |
SG193317A1 (en) * | 2011-03-30 | 2013-10-30 | Univ Texas | Methods and compositions for targeting adipose cells in mammals |
CN102188699A (zh) | 2011-05-06 | 2011-09-21 | 南京农业大学 | 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用 |
US20120058537A1 (en) | 2011-07-27 | 2012-03-08 | Fereidoun Mahboudi | Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1 |
RU2604810C2 (ru) | 2011-08-12 | 2016-12-10 | Тромбодженикс Н.В. | Варианты плазминогена и плазмина |
CN102532326B (zh) * | 2011-11-18 | 2017-06-09 | 南京大学 | 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用 |
CN103656630B (zh) | 2012-09-11 | 2015-07-08 | 江苏仁寿药业有限公司 | 一种提纯动物药材中纤溶酶并制备成中药组合物的方法 |
EP2914575B1 (en) | 2012-10-31 | 2020-10-14 | The Regents Of The University Of Michigan | Plasminogen activator-1 inhibitors and methods of use thereof |
US9134326B2 (en) | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
TWI689490B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
CN105008320A (zh) * | 2013-03-20 | 2015-10-28 | 埃莱万斯可再生能源科学股份有限公司 | 烷基酯和羧酸的酸催化低聚 |
CN104274449A (zh) | 2013-07-11 | 2015-01-14 | 无锡信达医疗器械有限公司 | 治疗肥胖症的药物组合物 |
MX2016001851A (es) | 2013-08-13 | 2016-05-16 | Sanofi Sa | Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos. |
TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途 |
WO2015026494A2 (en) | 2013-08-20 | 2015-02-26 | Trustees Of Dartmouth College | Methods for treating tissue fibrosis |
TWI705822B (zh) | 2014-12-19 | 2020-10-01 | 美商波麥堤克生物治療股份有限公司 | 包含纖維蛋白溶酶原之醫藥組合物及其用途 |
TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
US11090372B2 (en) | 2015-12-18 | 2021-08-17 | Talengen International Limited | Method of treating diabetic nephropathy comprising administering plasminogen |
ES2982294T3 (es) | 2015-12-18 | 2024-10-15 | Talengen Int Ltd | Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus |
WO2017101869A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肝组织损伤及其相关病症的方法 |
DK3395359T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose |
WO2017101871A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗心血管病的新方法 |
WO2017101870A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
JP7194440B2 (ja) | 2016-12-15 | 2022-12-22 | タレンゲン インターナショナル リミテッド | 心臓病変を改善するための方法 |
US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
TW201822812A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療肥胖症的方法 |
TWI868051B (zh) | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
-
2017
- 2017-06-19 TW TW106120501A patent/TW201822812A/zh unknown
- 2017-06-19 CA CA3047167A patent/CA3047167A1/en not_active Abandoned
- 2017-06-19 US US16/469,599 patent/US11547746B2/en active Active
- 2017-06-19 US US16/469,611 patent/US20190351033A1/en not_active Abandoned
- 2017-06-19 CN CN201780078105.0A patent/CN110366425A/zh active Pending
- 2017-06-19 US US16/470,174 patent/US20190328850A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089049 patent/WO2018107690A1/zh active Application Filing
- 2017-06-19 TW TW106120492A patent/TWI746580B/zh active
- 2017-06-19 TW TW106120465A patent/TWI750189B/zh active
- 2017-06-19 WO PCT/CN2017/089046 patent/WO2018107687A1/zh active Application Filing
- 2017-06-19 EP EP17881831.6A patent/EP3556391A4/en active Pending
- 2017-06-19 TW TW106120491A patent/TW201822805A/zh unknown
- 2017-06-19 JP JP2019532073A patent/JP7160351B2/ja active Active
- 2017-06-19 CA CA3047169A patent/CA3047169A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089045 patent/WO2018107686A1/zh active Application Filing
- 2017-06-19 EP EP17882244.1A patent/EP3556393A4/en active Pending
- 2017-06-19 CN CN201780078118.8A patent/CN110167583A/zh active Pending
- 2017-06-19 JP JP2019532070A patent/JP7158740B2/ja active Active
- 2017-06-19 CA CA3046664A patent/CA3046664C/en active Active
- 2017-06-19 EP EP17881180.8A patent/EP3556387A4/en active Pending
- 2017-06-19 TW TW106120464A patent/TWI684459B/zh active
- 2017-06-19 CN CN201780078127.7A patent/CN110114083A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089047 patent/WO2018107688A1/zh unknown
- 2017-06-19 JP JP2019532071A patent/JP7161217B2/ja active Active
- 2017-06-19 CN CN201780078126.2A patent/CN110114082A/zh active Pending
- 2017-06-19 US US16/469,618 patent/US11478535B2/en active Active
- 2017-06-19 WO PCT/CN2017/089043 patent/WO2018107684A1/zh unknown
- 2017-06-19 TW TW106120463A patent/TWI680764B/zh active
- 2017-06-19 TW TW106120498A patent/TW201822809A/zh unknown
- 2017-06-19 JP JP2019531975A patent/JP7214225B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089052 patent/WO2018107692A1/zh unknown
- 2017-06-19 WO PCT/CN2017/089051 patent/WO2018107691A1/zh active Application Filing
- 2017-06-19 CA CA3047168A patent/CA3047168A1/en active Pending
- 2017-06-19 TW TW110105040A patent/TW202123963A/zh unknown
- 2017-06-19 WO PCT/CN2017/089044 patent/WO2018107685A1/zh unknown
- 2017-06-19 EP EP17882245.8A patent/EP3556394A4/en active Pending
- 2017-06-19 TW TW106120499A patent/TW201822810A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030054988A1 (en) * | 2000-11-02 | 2003-03-20 | Weidong-Richard Ji | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
CN102482338A (zh) * | 2009-07-10 | 2012-05-30 | 斯路姆基因公司 | 纤溶酶原和纤溶酶的变体 |
CN103384722A (zh) * | 2011-01-05 | 2013-11-06 | 斯路姆基因公司 | 纤溶酶原和纤溶酶变体 |
US20130310305A1 (en) * | 2011-02-10 | 2013-11-21 | Trustees Of Dartmouth College | Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis |
Non-Patent Citations (3)
Title |
---|
BUTERA D等: "plasminogen isoform 1 precursor [Homo sapiens]", 《GENBANK》 * |
JI BEIER等: "Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism", 《EXPERIMENTAL BIOLOGY AND MEDICINE》 * |
QING XIAO等: "Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis", 《PROC. NAT. ACAD. SCI. USA》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
EP4349997A3 (en) | Anti-garp antibody | |
WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
HK1253734A1 (zh) | 用作RORγ激動劑和用於治療疾病的芳基二氫-2H-苯並[B][1,4]噁嗪磺酰胺和相關化合物 | |
CN110402150A (zh) | 一种预防和治疗骨质疏松的药物及其用途 | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
WO2016109217A3 (en) | Btk inhibitors | |
WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
EP4279128A3 (en) | Novel antibody binding to tfpi and composition comprising the same | |
WO2016142708A3 (en) | Pharmaceutical composition | |
CN110114081A (zh) | 一种改善心脏病变的方法 | |
MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
CN110167582A (zh) | 一种预防和治疗药物性肾损伤的方法 | |
CN110114080A (zh) | 一种预防和治疗皮肤纤维化的方法 | |
CN110520135A (zh) | 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途 | |
EP3586836A4 (en) | PHARMACEUTICAL COMPOSITION INTENDED TO PREVENT AND TREAT PANCREE CANCER, CONTAINING GOSSYPOL AND PHENFORMIN AS ACTIVE INGREDIENTS | |
JP2016069317A5 (ja) | 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物 | |
CN115666612A (zh) | 一种治疗亨廷顿病的方法和药物 | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
WO2020025657A9 (en) | Composition for use in the prevention and/or treatment of the genitourinary mucosa | |
CN107148277A (zh) | 一种抑制脂肪细胞分化和胰岛素耐受的药物 | |
WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |